<DOC>
	<DOCNO>NCT01255462</DOCNO>
	<brief_summary>This study ass safety , tolerability , serum pharmacokinetics intravitreal LFG316 patient advance age-related macular degeneration .</brief_summary>
	<brief_title>Intravitreal LFG316 Patients With Advanced Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Male female AMD patient 55 90 year old , inclusive . In either eye , diagnosis geographic atrophy choroidal neovascularization due AMD ETDRS best correct visual acuity 60 letter bad study eye . Retinal disease AMD study eye , investigator 's opinion , may pose safety risk interfere study . Choroidal neovascularization due cause AMD . In study eye , medium opacity interfere fundus image likely require surgery study period . Any following treatment study eye within 14 day prior dose : ranibizumab ( Lucentis ) , bevacizumab ( Avastin ) , pegaptanib ( Macugen ) , VEGF inhibitor ; OR likely requirement one treatment within 14 day LFG316 administration . Any follow within 30 day prior dose : photodynamic therapy treatment study eye ; extrafoveal juxtafoveal thermal laser photocoagulation study eye ; systemic topical ( ophthalmic ) steroid use study eye ; bacterial keratitis study eye ; OR intraocular surgery ( include cataract surgery ) fellow eye . Any follow within 90 day prior dose : intraocular surgery ( include cataract surgery ) study eye ; OR intravitreal periocular corticosteroid injection study eye . Participation another interventional clinical study , use experimental treatment AMD investigational new drug within 12 week prior start study treatment . Clinical trial solely involve overthecounter vitamin , supplement , diet exclude patient study participation . Any medical condition likely interfere patient 's participation study , likely cause serious adverse event study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>AMD ,</keyword>
	<keyword>ARMD ,</keyword>
	<keyword>Age-related Macular Degeneration ,</keyword>
	<keyword>Eye Disease ,</keyword>
	<keyword>Wet AMD ,</keyword>
	<keyword>Neovascular AMD ,</keyword>
	<keyword>Choroidal Neovascular Membrane ,</keyword>
	<keyword>Choroidal Neovascularization ,</keyword>
	<keyword>Drusen ,</keyword>
	<keyword>Geographic Atrophy ,</keyword>
	<keyword>Complement ,</keyword>
	<keyword>C5 ,</keyword>
	<keyword>Antibody</keyword>
</DOC>